PLASMABLASTIC LYMPHOMA

This study tests whether adding daratumumab to standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare and aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the com…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests whether adding daratumumab (a targeted antibody) to standard chemotherapy can better treat a rare and aggressive lymphoma called plasmablastic lymphoma. About 15 people with newly diagnosed disease, with or without HIV, will take part. The goal is to see if the c…

This early-phase trial tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to find the safest dose and understand side effects. Participants must have measurable disease and be well enough for dail…

This study will review the medical records of 200 people diagnosed with plasmablastic lymphoma, a rare blood cancer, between 2000 and 2022. Researchers want to learn more about the disease's features, treatments used, and what affects survival. No new treatments are given; the go…

This study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…